A Phase 3 interventional study of Oleogel-S10, non-adhesive wound dressing and Non-adhesive wound dressing only in Wounds, sponsored by Birken AG. Completed at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this phase III clinical trial was to compare intra-individually the efficacy, safety and tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only in accelerating the wound healing of Split-Thickness Skin Graft (STSG) donor sites.
Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in participants with skin lesions. Especially the results in a previous study with STSG donor sites suggested that Oleogel-S10 should be efficacious and safe in the treatment of superficial wounds.
The present phase III clinical trial in STSG donor sites was initiated to demonstrate wound healing progress, i.e., the time to healing and the grade of epithelialization of the wound.
In this study, STSG donor sites were separated into 2 wound halves. Randomly assigned, 1 wound half was treated with Oleogel-S10 and non-adhesive wound dressing, the other wound half with non-adhesive wound dressing only (standard of care).
Wound healing progress was documented by photos which were assessed by expert reviewers blind to the treatment of the wound halves.
2,218 studies on the registry are indexed under Wounds and Injuries; 440 are open to participants now.
This study's enrollment of 107 is above the median of 70 across 1,423 interventional studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →Birken AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
First submitted before Birken AG became part of Chiesi Farmaceutici S.p.A..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A split-thickness skin graft (STSG) donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Drug: Oleogel-S10, non-adhesive wound dressing
A STSG donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Device: Non-adhesive wound dressing only
1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Also known as: Episalvan®
Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Also known as: Mepilex®
Intra-individual Difference in Time to Wound Closure
Intra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing only. Independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound half that were taken before start of treatment, during wound dressing changes and at the end of treatment. Difference in time to wound closure was calculated for every individual participant as \[time taken for wound half treated with Oleogel-S10 to close\] - \[time taken for wound half treated with non-adhesive wound dressing to close\], i.e., results below 0 indicate earlier wound closure of Oleogel-S10 treatment. The overall mean difference in time to wound closure was calculated based on all mean differences in time to wound closure of individual participants. Hence, primary outcome data derived from mean difference in time to wound closure by participant.
Time frame: up to 4 weeks
Time From Surgery Until Wound Closure is Achieved
Time from surgery until wound closure is achieved, separately for wound halves treated with Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only. While outcome measure 1 (intra-individual difference in time to wound closure) was calculated based on mean intra-individual difference in time to wound closure in 107 participants with missing values replaced by a value of 0, for outcome measure 2 missing values were not replaced. For 5 of the 107 wounds data were missing, thus the reported values are calculated from 102 STSG donor site wound halves by intervention (Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only).
Time frame: up to 4 weeks
Percentage of Participants With Earlier Healing
Percentage of participants with earlier healing of wound area treated with Oleogel-S10 and non-adhesive wound dressing compared to non-adhesive wound dressing only
Time frame: up to 4 weeks
Percentage of Participants With Wound Closure at Different Time Points
For separate time points (Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28), the frequencies of wound areas which have reached wound closure were calculated.
Time frame: up to 4 weeks
Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator
A study team member assessed the progress of wound healing by treatment regimen and noted the degree of epithelialization (expressed in percent of the original wound size) at wound dressing changes on Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28.
Time frame: up to 4 weeks
Likert Scale Rating of Efficacy
Participants and investigators were asked to grade the efficacy of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only on a 5-point Likert scale (treatment with Oleogel-S10 is much more effective, treatment with Oleogel-S10 is more effective, both treatments have the same efficacy, non-adhesive wound dressing only is more effective, non-adhesive wound dressing only is much more effective).
Time frame: up to 4 weeks
Cosmetic Outcome at 3 and 12 Months After Surgery, Respectively
Blinded photographic evaluation which wound half resembles more closely the surrounding skin with regard to texture, redness, growth of hair, and pigmentation.
Time frame: 3 months and 12 months
Likert Scale Rating of Tolerability
Participants and investigators were asked to evaluate the tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only (standard of care) on a 5-point Likert scale (treatment with Oleogel-S10 is much better tolerated, treatment with Oleogel-S10 is better tolerated, both treatments are equally well tolerated, standard of care is better tolerated, standard of care is much better tolerated).
Time frame: up to 4 weeks
Pharmacokinetic (PK) Data (Number of Plasma Samples With Measurable Betulin Concentration)
Systemic presence/concentration of betulin in blood plasma samples. Plasma samples were collected in weekly intervals and at the end of treatment (when wound closure was achieved or at Day 28). Samples were analysed in a central laboratory with a validated LC-MS/MS method with a lower limit of quantification (LLOQ) of 1 ng/mL.
Time frame: up to 4 weeks
Pharmacokinetic (PK) Data (Plasma Betulin Concentration)
Systemic presence/concentration of betulin in blood plasma samples - values for the number of samples with measurable values in samples above the lower limit of quantification (LLOQ) of 1 ng/mL
Time frame: up to 4 weeks
Frequency of Adverse Events
Time frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).
Severity of Adverse Events
Adverse Events were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) as being mild (NCI CTCAE Grade 1), moderate (NCI CTCAE Grade 2), severe (NCI CTCAE Grade 3), life-threatening (NCI CTCAE Grade 4) or death (NCI CTCAE Grade 5).
Time frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).
Adverse Events by Relationship to Study Medication
Adverse events were assessed as being 'unlikely', 'possibly' or 'probably' related to study medication, 'not related' to study medication or the relationship to study medication was rated as 'unknown'.
Time frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).
Study participants were enrolled from 03 Aug 2012 to 01 Aug 2013 in 18 clinical centers in 6 countries: Germany (8 centers), Czech Republic (2 centers), Poland (1 center), Finland (1 center), Austria (2 centers), and Bulgaria (4 centers).
| Milestone | Entire Study Population |
|---|---|
| Started | 107 |
| Completed | 82 |
| Not completed | 25 |
| Withdrew: Lack of wound closure at day 28 | 15 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Did not adhere to protocol/procedures | 4 |
Intra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing only. Independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound half that were taken before start of treatment, during wound dressing changes and at the end of treatment. Difference in time to wound closure was calculated for every individual participant as \[time taken for wound half treated with Oleogel-S10 to close\] - \[time taken for wound half treated with non-adhesive wound dressing to close\], i.e., results below 0 indicate earlier wound closure of Oleogel-S10 treatment. The overall mean difference in time to wound closure was calculated based on all mean differences in time to wound closure of individual participants. Hence, primary outcome data derived from mean difference in time to wound closure by participant.
| days | Entire Study Population |
|---|---|
| Intra-individual Difference in Time to Wound Closure | -1.4 (-1.8 to -0.9) |
Time from surgery until wound closure is achieved, separately for wound halves treated with Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only. While outcome measure 1 (intra-individual difference in time to wound closure) was calculated based on mean intra-individual difference in time to wound closure in 107 participants with missing values replaced by a value of 0, for outcome measure 2 missing values were not replaced. For 5 of the 107 wounds data were missing, thus the reported values are calculated from 102 STSG donor site wound halves by intervention (Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only).
| Days from surgery until wound closure | Oleogel-S10, Non-adhesive Wound Dressing | Non-adhesive Wound Dressing Only |
|---|---|---|
| Time From Surgery Until Wound Closure is Achieved | 15.5 (14.2 to 16.8) | 17.1 (15.8 to 18.5) |
Percentage of participants with earlier healing of wound area treated with Oleogel-S10 and non-adhesive wound dressing compared to non-adhesive wound dressing only
| Percentage with earlier healing | Oleogel-S10, Non-adhesive Wound Dressing | Non-adhesive Wound Dressing Only |
|---|---|---|
| Percentage of Participants With Earlier Healing | 61.7 (51.8 to 70.9) | 7.5 (3.3 to 14.2) |
For separate time points (Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28), the frequencies of wound areas which have reached wound closure were calculated.
| Percentage with wound closure | Oleogel-S10, Non-adhesive Wound Dressing | Non-adhesive Wound Dressing Only |
|---|---|---|
| Day 7 | 2.0 (0.2 to 6.9) | 1.0 (0.0 to 5.3) |
| Day 10 | 25.5 (17.4 to 35.1) | 15.7 (9.2 to 24.2) |
| Day 14 | 49.0 (39.0 to 59.1) | 37.3 (27.9 to 47.4) |
| Day 18 | 70.6 (60.7 to 79.2) | 61.8 (51.6 to 71.2) |
| Day 21 | 77.5 (68.1 to 85.1) | 71.6 (61.8 to 80.1) |
| Day 28 | 94.1 (87.6 to 97.8) | 90.2 (82.7 to 95.2) |
A study team member assessed the progress of wound healing by treatment regimen and noted the degree of epithelialization (expressed in percent of the original wound size) at wound dressing changes on Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28.
| Area Percent of initial wound size | Oleogel-S10, Non-adhesive Wound Dressing | Non-adhesive Wound Dressing Only |
|---|---|---|
| Day 7 | 36.7 (30.4 to 43.0) | 28.1 (22.3 to 33.9) |
| Day 10 | 60.0 (52.9 to 67.1) | 49.9 (43.0 to 56.7) |
| Day 14 | 82.2 (76.9 to 87.5) | 74.3 (68.5 to 80.1) |
| Day 18 | 89.7 (85.4 to 93.9) | 82.3 (77.3 to 87.3) |
| Day 21 | 92.2 (88.6 to 95.9) | 85.8 (81.3 to 90.4) |
| Day 28 | 93.9 (90.6 to 97.2) | 90.0 (85.9 to 94.0) |
Participants and investigators were asked to grade the efficacy of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only on a 5-point Likert scale (treatment with Oleogel-S10 is much more effective, treatment with Oleogel-S10 is more effective, both treatments have the same efficacy, non-adhesive wound dressing only is more effective, non-adhesive wound dressing only is much more effective).
| Percentage of efficacy asssessments | Investigator Asssessment Day 7 | Investigator Assessment Day 14 | Investigator Assessment Day 21 | Investigator Assessment Day 28 | Investigator Assessment End of Treatment | Participant Assessment Day 7 | Participant Assessment Day 14 | Participant Assessment Day 21 | Participant Assessment Day 28 | Participant Assessment EoT |
|---|---|---|---|---|---|---|---|---|---|---|
| Oleogel-S10 much more effective | 15.0 (8.6 to 23.5) | 20.8 (13.4 to 30.0) | 19.6 (12.2 to 28.9) | 15.8 (9.1 to 24.7) | 16.3 (9.8 to 24.9) | 18.0 (11.0 to 26.9) | 15.8 (9.3 to 24.4) | 21.6 (13.9 to 31.2) | 20.0 (12.5 to 29.5) | 21.2 (13.8 to 30.3) |
| Oleogel-S10 more effective | 46.0 (36.0 to 56.3) | 49.5 (39.4 to 59.6) | 51.5 (41.2 to 61.8) | 52.6 (42.1 to 63.0) | 51.9 (41.9 to 61.8) | 44.0 (34.1 to 54.3) | 46.5 (36.5 to 56.7) | 42.3 (32.3 to 52.7) | 42.1 (32.0 to 52.7) | 41.3 (31.8 to 51.4) |
| Both treatments same efficacy | 31.0 (22.1 to 41.0) | 24.8 (16.7 to 34.3) | 25.8 (17.4 to 35.7) | 29.5 (20.6 to 39.7) | 28.8 (20.4 to 38.6) | 33.0 (23.9 to 43.1) | 31.7 (22.8 to 41.7) | 32.0 (22.9 to 42.2) | 34.7 (25.3 to 45.2) | 34.6 (25.6 to 44.6) |
| Standard of care (SOC) more effective | 8.0 (3.5 to 15.2) | 3.0 (0.6 to 8.4) | 1.0 (0.0 to 5.6) | 1.1 (0.0 to 5.7) | 1.9 (0.2 to 6.8) | 5.0 (1.6 to 11.3) | 4.0 (1.1 to 9.8) | 3.1 (0.6 to 8.8) | 3.2 (0.7 to 9.0) | 2.9 (0.6 to 8.2) |
| SOC much more effective | 0.0 (0.0 to 0.0) | 2.0 (0.2 to 7.0) | 2.1 (0.3 to 7.3) | 1.1 (0.0 to 5.7) | 1.0 (0.0 to 5.2) | 0.0 (0.0 to 0.0) | 2.0 (0.2 to 7.0) | 1.0 (0.0 to 5.6) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
Blinded photographic evaluation which wound half resembles more closely the surrounding skin with regard to texture, redness, growth of hair, and pigmentation.
| Percentage of wounds | Texture at 3 Months Follow-up | Hair Growth at 3 Months Follow-up | Pigmentation at 3 Months Follow-up | Redness at 3 Months Follow-up | Texture at 12 Months Follow-up | Hair Growth at 12 Months Follow-up | Pigmentation at 12 Months Follow-up | Redness at 12 Months Follow-up |
|---|---|---|---|---|---|---|---|---|
| Wound half treated with Oleogel-S10 | 36.8 (26.7 to 47.8) | 1.1 (0.0 to 6.2) | 41.4 (30.9 to 52.4) | 31.0 (21.5 to 41.9) | 13.3 (6.8 to 22.5) | 2.4 (0.3 to 8.4) | 20.5 (12.4 to 30.8) | 10.8 (5.1 to 19.6) |
| Wound half treated with wound dressing only | 5.7 (1.9 to 12.9) | 0.0 (0.0 to 0.0) | 6.9 (2.6 to 14.4) | 5.7 (1.9 to 12.9) | 2.4 (0.3 to 8.4) | 1.2 (0.0 to 6.5) | 8.4 (3.5 to 16.6) | 3.6 (0.8 to 10.2) |
| Both equal | 51.7 (40.8 to 62.6) | 97.7 (91.9 to 99.7) | 47.1 (36.3 to 58.1) | 58.6 (47.6 to 69.1) | 84.3 (74.7 to 91.4) | 96.4 (89.8 to 99.2) | 68.7 (57.6 to 78.4) | 85.5 (76.1 to 92.3) |
Participants and investigators were asked to evaluate the tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only (standard of care) on a 5-point Likert scale (treatment with Oleogel-S10 is much better tolerated, treatment with Oleogel-S10 is better tolerated, both treatments are equally well tolerated, standard of care is better tolerated, standard of care is much better tolerated).
| Percentage of participants | Investigator Asssessment Day 7 | Investigator Assessment Day 14 | Investigator Assessment Day 21 | Investigator Assessment Day 28 | Investigator Assessment End of Treatment | Participant Assessment Day 7 | Participant Assessment Day 14 | Participant Assessment Day 21 | Participant Assessment Day 28 | Participant Assessment EoT |
|---|---|---|---|---|---|---|---|---|---|---|
| Oleogeogel-S10 much better tolerated | 6.0 | 9.9 | 14.4 | 11.6 | 11.5 | 10.0 | 7.9 | 16.5 | 12.6 | 13.5 |
| Oleogel-S10 better tolerated | 38.0 | 40.6 | 32.0 | 32.6 | 33.7 | 34.0 | 37.6 | 29.9 | 31.6 | 30.8 |
| Both treatments equally well tolerated | 52.0 | 49.5 | 51.5 | 55.8 | 54.8 | 53.0 | 50.5 | 51.5 | 54.7 | 54.8 |
| SOC better tolerated | 4.0 | 0.0 | 2.1 | 0.0 | 0.0 | 3.0 | 4.0 | 2.1 | 1.1 | 1.0 |
| SOC much better tolerated | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Systemic presence/concentration of betulin in blood plasma samples. Plasma samples were collected in weekly intervals and at the end of treatment (when wound closure was achieved or at Day 28). Samples were analysed in a central laboratory with a validated LC-MS/MS method with a lower limit of quantification (LLOQ) of 1 ng/mL.
| Plasma Samples | Day 0 (Pre-dose) | Treatment Period |
|---|---|---|
| Samples below LLOQ (<1 ng/mL) | 105 | 272 |
| Samples above LLOQ (range in ng/mL) | 2 | 3 |
| Samples with no valid result | 0 | 6 |
Systemic presence/concentration of betulin in blood plasma samples - values for the number of samples with measurable values in samples above the lower limit of quantification (LLOQ) of 1 ng/mL
| Betulin (ng/mL) | Day 0 (Pre-dose) | Treatment Period |
|---|---|---|
| Pharmacokinetic (PK) Data (Plasma Betulin Concentration) | 2.1 (1.3 to 3.0) | 2.4 (1.2 to 4.6) |
| Participants with adverse events (%) | Entire Study Population |
|---|---|
| Adverse events (AEs) | 17.8 |
| Serious adverse events | 1.9 |
| AEs leading to discontinuation | 1.9 |
| Related AEs | 2.8 |
| Application site reactions | 8.4 |
Adverse Events were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) as being mild (NCI CTCAE Grade 1), moderate (NCI CTCAE Grade 2), severe (NCI CTCAE Grade 3), life-threatening (NCI CTCAE Grade 4) or death (NCI CTCAE Grade 5).
| Participants with adverse events (%) | Entire Study Population |
|---|---|
| Mild (CTCAE Grade 1) | 10.3 |
| Moderate (CTCAE Grade 2) | 4.7 |
| Severe (CTCAE Grade 3) | 4.7 |
| Life-Threatening (CTCAE Grade 4) | 0.0 |
| Death (CTCAE Grade 5) | 0.0 |
Adverse events were assessed as being 'unlikely', 'possibly' or 'probably' related to study medication, 'not related' to study medication or the relationship to study medication was rated as 'unknown'.
| Participants with adverse events (%) | Entire Study Population |
|---|---|
| 'Unlikely' related | 0.0 |
| 'Possibly' related | 2.8 |
| 'Probably' related | 0.0 |
| Unknown relationship | 0.0 |
| No relationship | 15.9 |
Collected over Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entire Study Population - Systemic Adverse Events (AE) | — | 1/107 (0.9%) | 0/107 (0%) |
| Oleogel-S10 Localized AE | — | 0/107 (0%) | 0/107 (0%) |
| Non-adhesive Wound Wound Dressing Localized AE | — | 0/107 (0%) | 0/107 (0%) |
| Localized AE Both Wound Halves | — | 1/107 (0.9%) | 0/107 (0%) |
| Event | Entire Study Population - Systemic Adverse Events (AE) | Oleogel-S10 Localized AE | Non-adhesive Wound Wound Dressing Localized AE | Localized AE Both Wound Halves |
|---|---|---|---|---|
| Diabetic footSkin and subcutaneous tissue disorders | 1/107 | 0/107 | 0/107 | 0/107 |
| Wound infectionInfections and infestations | 0/107 | 0/107 | 0/107 | 1/107 |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 65 |
| >=65 years | 40 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Median | 56 (18 to 86) |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 39 |
| Male | 68 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| Czech Republic | 40 |
| Austria | 4 |
| Finland | 3 |
| Poland | 2 |
| Bulgaria | 24 |
| Germany | 34 |
Plan to share: No
The record gives a start of Aug 2012, a primary completion of Aug 2013 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Episalvan